Amneal Pharmaceuticals, Inc.

What they do

Amneal operates three reportable segments: Affordable Medicines (retail generics, injectables and biosimilars across over 280 product families), Specialty (branded central nervous system and endocrine products such as CREXONT, RYTARY, UNITHROID and BREKIYA), and AvKARE (distribution of pharmaceuticals to U.S. federal government, retail and institutional markets). It operates principally in the United States, India and Ireland. Since a November 2023 reorganization it holds 100% of Amneal Pharmaceuticals, LLC and consolidates it.

Revenue drivers

• Affordable Medicines — Generics, injectables and biosimilars across 280-plus product families; the largest revenue base, with Q2 2026 net revenue up $56.5 million year over year driven by new launches and women's health.
• Specialty — Branded CNS and endocrine products sold through specialty sales teams; Q2 2026 net revenue rose $21.3 million, led by CREXONT (+$17.6 million), UNITHROID (+$5.9 million) and BREKIYA autoinjector (+$5.5 million), partly offset by RYTARY decline.
• AvKARE — Distribution to U.S. federal government, retail and institutional customers; Q2 2026 net revenue fell $6.1 million on lower low-margin distribution sales, partly offset by government-label growth.
• Generic launch timing and exclusivity — Management states generic revenues and gross margins are highest at launch and during market exclusivity, so new product introductions materially affect results and added competition pressures volume and price.

Recent performance

Q2 2026 net revenue was $796.2 million, up 9.9% from $724.5 million a year earlier, with gross margin of 42.0% versus 39.5%. GAAP net income attributable to Amneal was $58 million, or $0.18 diluted EPS, versus $22 million and $0.07; the 10-Q reported consolidated net income of $69.6 million. Adjusted EBITDA was $206 million, up 12%, and adjusted diluted EPS was $0.30 versus $0.25. Operating income rose 16.5% to $129.8 million, helped by lower R&D (-18.7%), while SG&A rose 19.7% on compensation and CREXONT/BREKIYA launch costs. Revenue for the twelve months through Q2 2026 ranged from $722.5 million in Q1 2026 to $814.3 million in Q4 2025.

Strategy

Amneal is pushing branded Specialty growth through CREXONT, launched September 2024, and BREKIYA autoinjector, FDA-approved May 2025 and launched in the U.S. in October 2025, alongside complex generics, injectables and biosimilars. It signed a 15-year collaboration with ApiJect in May 2025 to install blow fill seal manufacturing equipment at its Brookhaven, New York facility. A September 2024 Metsera agreement makes Amneal preferred global supply partner for weight loss medicines, with an exclusive license in India, parts of Southeast Asia, Africa and the Middle East; Metsera funds up to $100 million of two new Indian API and fill-finish plants. The company is also acquiring Kashiv Biosciences and intends to add $350 million of Term Loan B to fund part of the purchase price. In July 2026 it repriced its $2.084 billion Term Loan B, cutting pricing to SOFR plus 250 basis points from SOFR plus 300, expected to save about $12 million of annual cash interest and support reducing net leverage below 3.0x by 2028.

Risks

• Tariff exposure on pharmaceutical imports — A May 2026 Section 232 action imposed tariffs of up to 100% on certain branded finished dosage forms and APIs, and a July 21, 2026 proposal would raise generic drug tariffs to 100% for one year and 200% thereafter from August 2028, which could materially raise costs for products made outside the U.S.
• Product development and approval failure — Amneal's filings state future results depend on timely, cost-efficient development and FDA approval of new products, subject to clinical, patent-litigation, API-sourcing and manufacturing scale-up hurdles.
• Generic price erosion and competition — Generic revenue and margin are concentrated at launch and during limited competition, and additional market entrants generally reduce volume or pricing.
• Leverage and refinancing — Long-term debt was $2.56 billion at June 30, 2026, against $127.6 million of cash and $33.0 million of shareholder equity, leaving the company reliant on debt markets for repricing and the planned Kashiv financing.

Outlook

Management raised 2026 full-year guidance for the second time this year, to net revenue of $3.10-$3.20 billion and adjusted EBITDA of $750-$780 million, with adjusted diluted EPS of $0.96-$1.06. Operating cash flow guidance is unchanged at $350-$400 million ($375-$425 million excluding discrete items such as roughly $36 million of opioid settlement costs and Kashiv acquisition items), while capital expenditures were raised to $150 million from $110 million. The company says the pending Kashiv transaction will establish biosimilars as a new growth vertical, and it does not expect a material direct tariff impact on 2026 results based on announced timing.